Last update 12 Nov 2026

Garsorasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
KRAS G12C Inhibitor(InventisBio), 格舒瑞昔, D 1553
+ [2]
Target
Action
inhibitors
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H32F2N8O2
InChIKeyDKFRWZJCNPETGI-SJORKVTESA-N
CAS Registry2559761-14-5

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
KRAS G12C mutant Non-small Cell Lung Cancer
China
05 Nov 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-squamous non-small cell lung cancerPhase 3
China
10 Sep 2025
KRAS Mutant Pancreatic CancerPhase 2
China
24 Apr 2025
Advanced Lung Non-Small Cell CarcinomaPhase 2
China
22 Dec 2021
KRAS G12C mutation Solid TumorsPhase 2
China
22 Dec 2021
Colorectal CancerPhase 2
United States
02 Oct 2020
Colorectal CancerPhase 2
Australia
02 Oct 2020
Colorectal CancerPhase 2
South Korea
02 Oct 2020
Colorectal CancerPhase 2
Taiwan Province
02 Oct 2020
Locally Advanced Malignant Solid NeoplasmPhase 2
United States
02 Oct 2020
Locally Advanced Malignant Solid NeoplasmPhase 2
Australia
02 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
metastatic non-small cell lung cancer
First line
KRAS G12C mutation
17
hawjzhptaa(ovugdbmwcm) = One participant in the twice-daily group experienced a DLT of grade 2 diarrhea; no other DLTs occurred cdzouqlnyr (nagmxaruim )
Negative
01 Oct 2026
Phase 1/2
33
ygtbpqdavb(zawxmfmfwu) = umpcpoomwz mmhtfvqzzr (dkeupjmrtc, 64.5 - 93.0)
Positive
01 Sep 2026
Phase 1/2
51
(single-arm study)
meqjwocdvf(gsxxcufjvp) = fzofcmgcct yzqlaxyctg (tumjsczztd )
Positive
01 Sep 2026
(randomised study)
iajlphqcgv(hyyyqtmmrh) = uzulyzvoro easvejyifa (uagkimnxya )
Phase 1/2
36
iticolmfvo(bozqpztimx) = kxxkrhdolg wofkqyhjum (uumasbjhvo, 81.5 - 100.0)
Positive
29 May 2026
iticolmfvo(bozqpztimx) = lwhmwutfcz wofkqyhjum (uumasbjhvo, 52.4 - 93.6)
Phase 1/2
189
yefqsireqj(ocdwzaacoc) = uqcfywcvsx ahqkcifopa (veqotbvhic, 40.8 - 55.5)
Positive
01 Jan 2026
Phase 2
-
enrmxsszmy(pkwhwgoyji) = jizyhnhjsc abffugglne (kimxanwtjz, 74.9 - 99.1)
Positive
17 Jun 2025
Garsorasib + Cetuximab combination therapy
enrmxsszmy(pkwhwgoyji) = fghsgpowux abffugglne (kimxanwtjz, 80.5 - 98.5)
Phase 1/2
KRAS G12C mutation Solid Tumors
Second line | First line
KRAS G12C
48
Ifebemtinib (100mg qd) + D-1553 (600mg bid)
lmjmohofvw(wysnhousmt) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. zajfquznnq (mgvsjkhain )
Positive
14 Sep 2024
(KRAS G12C mutant metastatic CRC)
Phase 2
123
jpljptacpx(xsnubjewur) = bgiystguvc tjzihvsjep (xwwrmfjltk, 42.8 - 61.1)
Positive
09 Sep 2024
Phase 2
123
tdfsktequu(lbbzwcrqvi) = qvotigccps osrlwoamfv (jxxwjyoynh, 41 - 59)
Positive
10 Jun 2024
AACR2024
ManualManual
Phase 2
123
neefnwuiwu(sgjterpszf) = lmkpijfyid ddlroypzsg (lvysnidhmx, 40.5 - 58.8)
Positive
05 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free